Sang­amo ties up with a new­com­er in the cell ther­a­py field; Lab­Corp wins FDA au­tho­riza­tion of lat­est Covid-19 test

→ A year af­ter its launch, up­start cell con­ver­sion biotech Mo­gri­fy has inked a col­lab­o­ra­tion deal with Sang­amo, which plans to put its own plat­form tech to work in de­vel­op­ing al­lo­gene­ic im­munother­a­peu­tic CAR-Tregs. Mo­gri­fy raised $20 mil­lion to put its cell tech to the test, look­ing to con­vert cells in­to oth­er types of cells for use in a va­ri­ety of ther­a­peu­tic ways. It’s one of the lat­est ad­vances in a field boot­ed up by Shinya Ya­mana­ka’s break­through work on stem cells 14 years ago. Mo­gri­fy gets an un­spec­i­fied up­front and a high-pro­file part­ner in the al­liance.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.